NCE-001

NCE-001 is a small molecule drug developed by Ampio Pharmaceuticals. It is a proprietary methylphenidate derivative designed to stimulate protein phosphatase 2A (PP2A), an intracellular phosphatase involved in inflammation, angiogenesis, and cell proliferation pathways. The drug has demonstrated significant in vitro effects on aggressive cancer cells from glioblastoma multiforme, renal cell carcinoma, and inflammatory breast cancer lineages. Its mechanism of action centers on activating PP2A to modulate these critical cellular processes. NCE-001 has been considered for the treatment of neoplasms (cancers) and nervous system diseases such as Alzheimer’s disease. As of the latest updates, its highest development status is preclinical[2][5][6].